Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma
Status:
Recruiting
Trial end date:
2023-08-27
Target enrollment:
Participant gender:
Summary
This study is a single-center, prospective, one-arm clinical study, which is planned to be
carried out in Cancer Hospital of Chinese Academy of Medical Sciences. The patients with
locally advanced or metastatic leiomyosarcoma who are inoperable are enrolled, aiming at the
effectiveness and safety of temozolomide for injection combined with epirubicin as the
first-line treatment for advanced leiomyosarcoma.